Xanthoangelol and 4-hydroxyderricin are the major active principles of the inhibitory activities against monoamine oxidases on angelica keiskei K

Biomolecules and Therapeutics

Volumn 21, Issue 3, 2013, Pages 234-240

  Kim, Ji Ho ^a   Son, Yeon Kyung ^a   Kim, Gun Hee ^b   Hwang, Keum Hee ^b  

^a Daewoong Pharmaceutical Co Ltd   (South Korea)

^b Duksung Women's University   (South Korea)

Author keywords

4 hydroxyderricin; Angelica keiskei koidzumi; Cynaroside; Dopamine hydroxylase inhibitor; Monoamine oxidase inhibitor; Xanthoangelol

Indexed keywords

4 HYDROXYDERRICIN; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANGELICA KEISEI EXTRACT; CHALCONE DERIVATIVE; DOPAMINE BETA MONOOXYGENASE; IPRONIAZID; LUTEOLIN 7 GLUCOSIDE; MONOAMINE OXIDASE INHIBITOR; PLANT EXTRACT; SELEGILINE; UNCLASSIFIED DRUG; XANTHOANGELOL;

ANGELICA; ANGELICA KEISKEI; ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FRACTIONATION; IC 50; LIVER MITOCHONDRION; MALE; NONHUMAN; PLANT LEAF; PLANT STEM; RAT;

ANGELICA KEISKEI; GYMNOMYZA;

EID: 84878430947     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2012.100     Document Type: Article

References (23)

1. Akihisa, T., Tokuda, H., Hasegawa, D., Ukiya, M., Kimura, Y., Enjo, F., Suzuki, T. and Nishino, H. (2003) Chalcones, coumarins, and flavanones from the exudate of Angelica keiskei and their chemopreventive effects. Cancer Lett. 201, 133-137.
2. Baba, K., Nakata, K., Taniguchi, M., Kido, T. and Kozawa, M. (1990) Chalcones from Angelica keiskei. Phytochemistry 29, 3907-3910.
3. Birkmayer, W., Knoll, J., Riederer, P. and Youdim, M. (1983) (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod. Probl. Pharmacopsychiatry 19, 170-176.
4. Fujita, T., Sakuma, S., Sumiya, T., Nishida, H., Fujimoto, Y., Baba, K. and Kozawa, M. (1992) The effects of xanthoangelol E on arachidonic acid metabolism in the gastric antral mucosa and platelet of the rabbit. Res. Comun. Chem. Pathol. Pharmacol. 77, 227-240.
5. Han, Y. N., Choo, Y. S., Lee, Y. C., Moon, Y. I., Kim, S. D. and Choi, J. W. (2001) Monoamine oxidase B inhibitors from the fruits of Opuntia ficus-indica var. saboten. Arch. Pharm. Res. 24, 51-54.
6. Kim, O. K., Kung, S. S., Park, W. B., Lee, M. W. and Ham, S. S. (1992) The nutritional components of aerial whole plant and juice of Angelica keiskei. Korean J. Food Sci. Technol. 25, 592-596.
7. Kim, J. H., Kim, G. H. and Hwang K. H. (2012) Monoamine oxadase and dopamine β-hydroxylase inhibitors from the fruits of gardenia jasminoides. Biomol. Ther. 20, 214-219.
8. Kitaichi, Y., Inoue, T., Nakagawa, S., Boku, S., Izumi, T. and Koyama, T. (2010) Combined treatment with MAO-A inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine. Euro. J. Pharmacol. 637, 77-82.
9. Larsen, J. K., Gjerris, A. P., Anderson J. Bille, A., Christensen, E. M., Hoyer, E., Hensen, H., Mejlhede, A., Langagergaard, A., Laursen, A. L., Nilkantan, B., Olafsson, K., Severin, B. and Rafaelsen, O. J. (1991) Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasing atypical depression. Acta Psychiatr. Scand. 84, 564-570.
10. Lipper, S., Murphy, D. L., Slater, S. and Buchsbaum, M. S. (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminart evaluation. Psychopharmacol. (Berl) 62, 123-128.
11. Lotufo-Neto, F., Trivedi, M. and Thase, M. E. (1999) Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofarnmine for the treatment of depression. Neuropsychopharmacology 20, 226-247.
12. Mann, J. J., Aarons S. F., Wilner, P. J., Keilp, J. G., Sweeney, J. A., Pearlstein, T., Frances, A. J., Kocsis, J. H. and Brown, R. P. (1989) A controlled study of the antidepressant efficacy and side effects of (-) deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry 46, 45-50.
13. Meyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N. and Houle, S. (2009) Brain monoamine oxidase a binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 66, 1304-1312.
14. Ogawa, H., Ohno, M. and Baba, K. (2005) Hypotensive and lipidregulatory actions of 4-hydroxyderricin, a chalcone from Angelca keiskea, in stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 32, 19-23.
15. Okuyama, T., Takata, M., Takayasu, J., Hasegawa, T., Tokuda, H., Nishino, A., Nishino, H. and Iwahima, A. (1991) Anti-tumor-promotion by principles obtained from Angelica keiskei. Planta Med. 57, 242-246.
16. Park, J. C., Cho, Y. S., Park, S. K., Park, J. R., Chun, S. S., Ok, K. D. and Choi, J. W. (1995) Isolation of flavone-7-O-glycosides from the aerial parts of Anglica keiskei and anti-hyperlipidmic effect. Korean J. Pharmacogn. 26, 337-343.
17. Park, J. R., Park, S. K., Cho, Y. S., Chun, S. S., Choi, S. H. and Park J. C. (1997) Effects of Angelica keiskei on lipid metabolism in rats. J. Korean Soc. Food Sci. Nutr. 26, 308-313.
18. Quitkin, F., Rifkin, A. and Klein, D. F. (1979) Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch. Gen. Psychiatry 36, 749-760.
19. Riederer, P., Reynolds, G. P., Jellinger, K., Seemann, D. and Danielczyk, W. (1983). Tranylcypromine isomers in Parkinson's disease: effect of low doses on monoamine oxidase inhibition and blood pressure response. Mod. Probl. Pharmacopsychiatry 19, 154-161.
20. Rigal, F. and Zarifian, E. (1983) MAO inhibitors in psychiatric therapy: effects and side effects. Mod. Probl. Pharmacopsychiatry 19, 162-169.
21. Shimizu, E., Hayashi, A., Takahashi, R., Aoyagi, Y., Murakami, T. and Kimoto, K. (1999) Effects of angiotensin I-converting enzyme inhibitor from Ashitaba (Angelica keiskei) on blood pressure of spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 45, 375-383.
22. Stern, G. M., Lees, A. J., Hardie, R. and Sandler, M. (1983) Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. Acta Neurol. Scand. Suppl. 95, 113-116.
23. Wimbiscus, M., Kostenko, O. and Malone, D. (2010) MAO inhibitors: Risks, benefits, and lore. Cleve. Clin. J. Med. 77, 859-882.